Anupam Rasayan India Limited has announced the strategic acquisition of Bliss GVS Pharma Limited to bolster its pharmaceutical presence. The deal aims to leverage Bliss GVS Pharma’s strong portfolio of 150+ brands and global reach. This expansion grants Anupam Rasayan entry into new therapeutic segments and regulated markets, supported by a robust pipeline of 62+ molecules. The acquisition is expected to drive significant revenue growth through integrated manufacturing capabilities and expanded capacity utilization.
Strategic Deal Overview
Anupam Rasayan India Limited is acquiring a controlling stake in Bliss GVS Pharma Limited, an established pharmaceutical formulations company incorporated in 1984. The transaction involves an acquisition of 43.3% to 48.2% of the company, supplemented by an Open Offer to public shareholders. The deal is financed through a combination of a Rs 300 crore term loan and a non-controlling, non-voting equity instrument for the balance amount, ensuring seamless consolidation.
Synergies and Growth Drivers
This partnership creates significant synergies by integrating Bliss GVS Pharma’s extensive manufacturing footprint across six facilities in Maharashtra with Anupam’s operational expertise. Key benefits include:
- Market Expansion: Immediate access to 50+ therapeutic segments, including cardiovascular, antidiabetic, and anti-malarial treatments.
- Regulated Market Entry: Capitalizing on Bliss GVS Pharma’s existing global accreditations, including US FDA, EU GMP, and TGA Australia.
- Operational Leverage: A significant opportunity to ramp up current capacity utilization, which stands at approximately 30%, alongside forward integration to optimize costs.
Performance Highlights
Bliss GVS Pharma enters this acquisition with a strong financial profile. As of March 31, 2026, the company reported revenue of Rs 927 crore and zero net debt. With Rs 167 crore in cash and cash equivalents and a healthy cash flow from operations of Rs 139 crore, the business provides a stable foundation for Anupam Rasayan to pursue its expansion strategy in high-entry-barrier pharmaceutical markets.
Source: BSE
